On March 20, 2012, the U.S. Supreme Court reshaped the landscape of patent law with its long-awaited decision in Mayo Collaborative Services v. Prometheus Laboratories. The Court ruled that certain claims of patents licensed to Prometheus, claims that related to the use of thiopurine drugs in the treatment of autoimmune diseases such as Crohn’s disease, were invalid because they did not constitute patent eligible subject matter.
So, what is still considered patentable subject matter, in light of Mayo v. Prometheus? Click the links below to find out.
This post on Patents was authored by Founders Workbench.